Brain cancer diagnostics sales will rise through 2036, driven by magnetic resonance spectroscopy at 34.5% of the test type segment in 2026, supported by sustained demand from core end-use applications. The market was valued at USD 5.73 billion in 2025 and is expected to be worth USD 18.45 billion by 2036.